TABLE 2.
Neutralizing capacity of plasma collected in April/May 2020 against SARS‐CoV‐2 variants of concern by PRNT50
| Specimen # | Wild‐type titer category | PRNT50 Wuhan | PRNT50 alpha | PRNT50 beta | PRNT50 gamma | PRNT50 delta |
|---|---|---|---|---|---|---|
| CIHR001226 | Low titer a | <1:20 | <1:20 | <1:20 | <1:20 | <1:20 |
| CIHR002290 | 1:20 | 1:40 | <1:20 | <1:20 | 1:20 | |
| CIHR002377 | 1:40 | 1:40 | <1:20 | 1:20 | 1:40 | |
| CIHR000491 | High titer b | 1:160 | 1:320 | <1:20 c | <1:20 c | 1:160 |
| CIHR000496 | 1:320 | 1:320 | 1:40 c | <1:20 c | 1:160 | |
| CIHR000503 | 1:160 | 1:160 | 1:160 | 1:80 | 1:160 | |
| CIHR002076 | 1:640 | 1:640 | 1:160 | 1:320 | 1:640 | |
| CIHR002309 | 1:640 | 1:320 | 1:20 c | 1:160 | 1:160 | |
| CIHR002774 | 1:640 | 1:160 | 1:80 c | 1:40 c | 1:160 |
a
All low value specimens had a D614 wild‐type PRNT50 (NML) of 1:40.
b
CIHR000491, CIHR000496, and CIHR000503 had D614G wild‐type PRNT50 results of 1:160 (NML). CIHR002076, CIHR002309, and CIHR0002774 had D614 wild‐type PRNT50 results of 1:640 (NML).
c
Denotes a > fourfold drop in PRNT50 titers compared to Wuhan wild‐type.